3 studies found for:    BT-062
Show Display Options
Rank Status Study
1 Recruiting BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: BT062 , intravenous administration
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Biotest Pharmaceuticals Corporation;   Biotest
Study Start: July 2012
Primary Completion: July 2014
2 Active, not recruiting Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: BT062
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Biotest Pharmaceuticals Corporation;   Biotest
Study Start: August 2010
Primary Completion: July 2013
3 Completed Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: BT062
Phase: Phase 1
Sponsor/Collaborators: Biotest Pharmaceuticals Corporation;   Biotest
Study Start: August 2008
Primary Completion: April 2012

Indicates status has not been verified in more than two years